Coya Therapeutics Inc (COYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 28,130 | 29,757 | 35,531 | 38,340 | 31,057 |
| TOTAL | $32,025 | $33,428 | $38,373 | $44,308 | $35,506 |
| Non-Current Assets | |||||
| PPE Net | 18 | 25 | 32 | 39 | 45 |
| TOTAL | $18 | $25 | $32 | $39 | $45 |
| Total Assets | $32,043 | $33,453 | $38,405 | $44,347 | $35,552 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,112 | 931 | 1,690 | 1,588 | 337 |
| Accrued Expenses | 1,639 | 2,839 | 1,810 | 1,388 | 1,409 |
| TOTAL | $3,667 | $4,501 | $4,341 | $3,825 | $2,319 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 917 | 731 | 841 | 848 | 573 |
| TOTAL | $1,091 | $641 | $694 | $945 | $1,223 |
| Total Liabilities | $4,758 | $5,142 | $5,035 | $4,770 | $3,542 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 20,924 | 16,725 | 16,725 | 16,725 | 16,707 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -56,255 | -54,139 | -48,044 | -40,737 | -37,821 |
| TOTAL | $27,285 | $28,310 | $33,370 | $39,577 | $32,010 |
| Total Liabilities And Equity | $32,043 | $33,453 | $38,405 | $44,347 | $35,552 |